Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies
Open Access
- 22 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (9) , 1270-1280
Abstract
Key Points: No correlation was observed between pruritus severity and serum phosphate or response to placebo or difelikefalin in patients with CKD-associated pruritus undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline serum phosphate. Background: CKD-associated pruritus (CKD-aP) has historically been associated with elevated serum phosphate (sP). Difelikefalin is a novel antipruritic agent approved for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis. This post hoc analysis used data from phase 3 difelikefalin studies (KALM-1, KALM-2, and open-label Study 3105) to assess the role of sP in the pathogenesis of CKD-aP and whether difelikefalin ameliorates CKD-aP in patients with and without elevated sP. Methods: Patients with moderate-to-severe CKD-aP undergoing hemodialysis with baseline sP data were included in the analysis (KALM-1 and KALM-2, n=845; Study 3105, n=220). Assessments included correlation between 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) score and sP. Results: In KALM-1 and KALM-2, baseline characteristics in the overall population were similar between patients with sP ≤5.5 and >5.5 mg/dl; no significant correlation was observed between WI-NRS and sP at baseline or in week 12. In patients receiving placebo, no correlation was observed between WI-NRS and sP at baseline or between their change from baseline to week 12 (all P < 0.05). Clinically meaningful (≥3-point) reductions from baseline to week 12 in WI-NRS scores were reported by more patients receiving placebo with baseline sP ≤5.5 mg/dl than >5.5 mg/dl (least squares mean 37.2% versus 27.4%; odds ratio [95% confidence interval], 0.63 [0.41 to 0.97]; P = 0.04). A greater proportion of patients treated with difelikefalin achieved a ≥3-point WI-NRS reduction from baseline to week 12 versus placebo and was similar between sP ≤5.5 and >5.5 mg/dl subgroups (least squares means 51.1% versus 57.6% [P = 0.20]). No significant relationships between sP and WI-NRS in patients receiving difelikefalin were identified in Study 3105 at any time point. Conclusions: No correlation was observed between pruritus severity and sP or response to placebo or difelikefalin in patients with CKD-aP undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline sP.Keywords
Funding Information
- Vifor Pharma (N/A)
- Vifor Pharma (N/A)
This publication has 26 references indexed in Scilit:
- Longitudinal Predictors of Uremic PruritusJournal of Renal Nutrition, 2013
- Uraemic Pruritus: Relief of Itching by Gabapentin and PregabalinNephron Clinical Practice, 2013
- Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney DiseaseJAMA, 2011
- A Longitudinal Study of Uremic Pruritus in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2010
- Uraemic PruritusDrugs, 2009
- Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrology Dialysis Transplantation, 2006
- Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patientsKidney International, 2006
- A study on pruritus after parathyroidectomy for secondary hyperparathyroidism1Journal of the American College of Surgeons, 2000
- Optimal dialysis improves uremic pruritusAmerican Journal of Kidney Diseases, 1995
- Uremic Pruritus: Skin Divalent Ion Content and Response to Ultraviolet PhototherapyAmerican Journal of Kidney Diseases, 1985